Loading...
Docoh

Redhill Biopharma (RDHL)

RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® for the treatment of travelers' diarrhea in adults. RedHill's key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (Yeliva®, ABC294640), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (v) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB-106, an encapsulated bowel preparation.

RDHL stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

17 Mar 22
1 Oct 22
31 Dec 22
Quarter (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
13F holders Current Prev Q Change
Total holders 1 1
Opened positions 0 0
Closed positions 0 1 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 425.73M 425.73M
Total shares 69M 69M
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
CMOPF Cosmo Pharmaceuticals 69M $425.73M 0.0%
Largest transactions Shares Bought/sold Change
CMOPF Cosmo Pharmaceuticals 69M 0 0.0%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AbbVie, Aboud, Abraham, ACA, accrual, acknowledge, Africa, anticancer, Arabia, ASX, Atlanta, Avalo, AVLO, Bahrain, Beta, BID, Biolight, Cantor, cargo, cc, CEO, chair, checkpoint, closure, CMO, CN, CODM, constitutionality, contributor, Council, Delta, dexamethasone, dock, domain, ease, EBITDA, embedded, FACP, faster, Fellow, Fitzgerald, Fraction, front, Gaelan, GAG, Gamma, gathered, Ghassan, Gulf, hard, hazard, HFNC, HHS, IBOR, IdoMoo, Immunol, Incyte, Indonesia, Inline, inquiring, inspired, InterBank, interstitial, intolerant, irrespective, isocitrate, ivosidenib, Korean, Kukbo, Kuwait, Levitt, load, loading, LungFit, macroeconomic, Maker, Malaysia, mask, medRxiv, MHRA, Minovia, molnupiravir, momentum, movnatik®, Movntik, Nano, nirmatrelvir, nodular, Nuzyra, obstruction, offload, Oman, onset, outpatient, overtime, Paratek, PCR, PCT, PhD, Photomyne, port, predominantly, prespecified, Qatar, questionnaire, Ratnatunga, reconsider, reevaluated, reexamining, renal, repurchase, RFR, ribonucleic, Rinvoq, RNA, robustly, Saudi, saving, screening, seal, Servier, Seventeen, shell, shortly, steadily, subset, supplementary, Switzerland, synethesizing, Tenax, TENX, Thailand, thought, Tibsovo, tightening, transmembrane, turnover, UAE, Ukraine, unaffected, undergone, unilateral, unilaterally, unintended, unnecessary, upadacitinib, ureteral, UUO, variant, viability, Vietnam, wage, Weebit
Removed: ADVANZ, Amneal, Atropine, attend, begun, biologically, BrainTree, capability, CRO, crofelemer, dealer, DESI, Donnatal, Entera, EnteraGam, esomeprazole, fatigue, Florida, Fuji, GERD, Gold, Hikma, Hydrobromide, hyoscyamine, invasion, Jaguar, justification, leasing, maya, meter, Mytesi, Napo, observable, observing, Oxley, ParaPRO, peripheral, Phenobarbital, physically, player, portrayal, relied, retained, reviewed, rigorously, Scopolamine, Silver, spanning, strontium, Suite, summarizing, synthesizing, Tabular, TBC, unconsolidated, unobservable, unreasonably, valuation, varied, Vermont, warehouse
Proxies
No filings

Patents

Utility
Sphingosine kinase 2 inhibitor for treating coronavirus infection
21 Jun 22
The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Utility
Sphingosine Kinase 2 Inhibitor for Treating Coronavirus Infection In Moderately Severe Patients with Pneumonia
16 Jun 22
The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Utility
All-in-one Fixed-dose Combination for Treating Helicobacter Pylori Infection
3 Mar 22
Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein.
Utility
Sphingosine Kinase 2 Inhibitor for Treating Coronavirus Infection
3 Feb 22
The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
Utility
Triple Antibiotic Fixed-dose Combination Products, Dosing Regimen, Methods, and Kits for Treating Pulmonary Non-tuberculosis Mycobacterial Infections
30 Dec 21
A fixed-dose combination drug product formulated for oral delivery comprises a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine and a fixed 40.0 mg dose of rifabutin.